RMP
GILD icon

Richards, Merrill & Peterson’s Gilead Sciences GILD Stock Holding History

Richards, Merrill & Peterson’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-110
Closed -$12.3K – 310
2025
Q1 		$12.3K Hold
110
– – 0.01% 380
2024
Q4 		$10.2K Buy
+110
New +$9.9K 0.01% 376

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Richards, Merrill & Peterson's GILD Position: Q2 2025 in Review

Richards, Merrill & Peterson sold out of Gilead Sciences (GILD) in Q2 2025, closing a stake of 110 shares — an estimated $12.3K sold.

Richards, Merrill & Peterson first reported a position in GILD in Q4 2024 and held it in 2 quarters. The position peaked at $12.3K in Q1 2025. 2,023 funds tracked by Wall St. Rank hold GILD as of Q2 2025.

  • Richards, Merrill & Peterson reported no remaining Gilead Sciences position as of Q2 2025 after selling out during the quarter.
  • Richards, Merrill & Peterson sold 110 Gilead Sciences shares in Q2 2025, an estimated $12.3K.
  • Richards, Merrill & Peterson first reported a position in Gilead Sciences in Q4 2024 and held it in 2 quarters.
  • Richards, Merrill & Peterson's Gilead Sciences position peaked at $12.3K in Q1 2025.
  • 2,023 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2025.

Based on Richards, Merrill & Peterson's 13F filing for Q2 2025, filed 31 Jul 2025.